Bevacizumab 認識標靶藥品Bevacizumab
2024/1/22
Bevacizumab is a monoclonal antibody that targets to the protein called endothelial growth factor (VEGF), thereby inhibiting the binding of VEGF to its receptors. As a result, bevacizumab prevents the growth of the new blood vessels, thereby reducing oxygen and nutrients to the tumor. This can interfere with cancer cell growth and expansion.